Retrospective Study of the Use of Heparins in Pregnant Women and in vitro Testing on the HCT 116 Colorectal Carcinoma Cell Line.

Pub Date : 2024-01-30 eCollection Date: 2024-01-01 DOI:10.2478/jccm-2024-0009
Felicia Fiat, Diana-Aurora Arnautu, Brenda Cristina Bernad, Alina Anton, Iasmina Marcovici, Alexandra-Denisa Semenescu, Elena Silvia Bernad
{"title":"Retrospective Study of the Use of Heparins in Pregnant Women and <i>in vitro</i> Testing on the HCT 116 Colorectal Carcinoma Cell Line.","authors":"Felicia Fiat, Diana-Aurora Arnautu, Brenda Cristina Bernad, Alina Anton, Iasmina Marcovici, Alexandra-Denisa Semenescu, Elena Silvia Bernad","doi":"10.2478/jccm-2024-0009","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pregnant women manifest an increased risk of developing coagulation disorders. Unfractionated heparin (HEP) and low-molecular-weight heparin (LMWHep) are considered as selective medication in the case of pregnancy which needs anticoagulant treatment. In addition to anticoagulant properties, HEP and its derivatives manifest other properties including anti-cancer potential. According to Globocan's latest data, colorectal cancer (CRC) is the second most encountered form of malignancy in the case of women, manifesting some special particularities, as confusion of symptoms from cancer with symptoms encountered normally in pregnant women (such as constipation or rectal bleeding), delayed diagnosis because of limitations imposed both for the fetus and for the mother, and the need for special treatment.</p><p><strong>Aim: </strong>The aim of the present work is to follow the incidence and safety of consumption of HEP and LMWHep in the case of pregnant women and to analyze their potential on the HCT 116 colorectal carcinoma cells.</p><p><strong>Results: </strong>Analyzing the consumption of heparins in case of pregnant women hospitalized from 01.01.2022 to 31.12.2022 at the Pius Brînzeu\" Emergency Clinical Hospital from Timisoara, Obstetrics and Gynecology Clinic I, it was observed that 44,6% of the patients were administered the following medication and no administration risks were observed. When tested on HCT 116 cells, heparins manifested a significant anti-migratory effect (with wound healing rates of 2,6%, when tested with HEP 100 UI concentration and 14.52% wound healing rates in case of fraxiparine 100 UI). In addition, different signs of apoptosis were observed, suggesting the pro-apoptotic potential of the tested substances.</p><p><strong>Conclusions: </strong>Heparins remain the preferred medication to be administered to pregnant women with the potential for coagulation disorders, showing a high safety profile. Testing on the cancerous line of colorectal carcinoma highlights important properties that stimulate future studies, to establish the anti-tumor potential and the exact mechanism of action.</p>","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11193965/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/jccm-2024-0009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Pregnant women manifest an increased risk of developing coagulation disorders. Unfractionated heparin (HEP) and low-molecular-weight heparin (LMWHep) are considered as selective medication in the case of pregnancy which needs anticoagulant treatment. In addition to anticoagulant properties, HEP and its derivatives manifest other properties including anti-cancer potential. According to Globocan's latest data, colorectal cancer (CRC) is the second most encountered form of malignancy in the case of women, manifesting some special particularities, as confusion of symptoms from cancer with symptoms encountered normally in pregnant women (such as constipation or rectal bleeding), delayed diagnosis because of limitations imposed both for the fetus and for the mother, and the need for special treatment.

Aim: The aim of the present work is to follow the incidence and safety of consumption of HEP and LMWHep in the case of pregnant women and to analyze their potential on the HCT 116 colorectal carcinoma cells.

Results: Analyzing the consumption of heparins in case of pregnant women hospitalized from 01.01.2022 to 31.12.2022 at the Pius Brînzeu" Emergency Clinical Hospital from Timisoara, Obstetrics and Gynecology Clinic I, it was observed that 44,6% of the patients were administered the following medication and no administration risks were observed. When tested on HCT 116 cells, heparins manifested a significant anti-migratory effect (with wound healing rates of 2,6%, when tested with HEP 100 UI concentration and 14.52% wound healing rates in case of fraxiparine 100 UI). In addition, different signs of apoptosis were observed, suggesting the pro-apoptotic potential of the tested substances.

Conclusions: Heparins remain the preferred medication to be administered to pregnant women with the potential for coagulation disorders, showing a high safety profile. Testing on the cancerous line of colorectal carcinoma highlights important properties that stimulate future studies, to establish the anti-tumor potential and the exact mechanism of action.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
孕妇使用肝素的回顾性研究以及对 HCT 116 大肠癌细胞系的体外测试。
导言孕妇发生凝血功能障碍的风险增加。非减量肝素(HEP)和低分子量肝素(LMWHep)被认为是妊娠期需要抗凝治疗的选择性药物。除了抗凝特性外,HEP 及其衍生物还具有其他特性,包括抗癌潜力。根据 Globocan 的最新数据,结肠直肠癌(CRC)是女性第二大恶性肿瘤,具有一些特殊性,如癌症症状与孕妇的正常症状(如便秘或直肠出血)相混淆,由于对胎儿和母亲的限制而延误诊断,以及需要特殊治疗。目的:本研究旨在跟踪孕妇服用 HEP 和 LMWHep 的发生率和安全性,并分析它们对 HCT 116 大肠癌细胞的潜在影响:对 2022 年 1 月 1 日至 2022 年 12 月 31 日期间在蒂米什瓦拉 Pius Brînzeu 紧急临床医院妇产科第一诊所住院的孕妇使用肝素的情况进行了分析,发现 44.6%的患者使用了以下药物,且未发现用药风险。在对 HCT 116 细胞进行测试时,肝素具有显著的抗迁移效果(使用浓度为 100 UI 的 HEP 进行测试时,伤口愈合率为 2.6%;使用浓度为 100 UI 的 fraxiparine 进行测试时,伤口愈合率为 14.52%)。此外,还观察到不同的细胞凋亡迹象,这表明受测物质具有促进细胞凋亡的潜力:肝素类药物仍然是可能出现凝血功能障碍的孕妇的首选药物,具有很高的安全性。对结肠直肠癌癌系的测试突出了其重要特性,促进了未来的研究,以确定其抗肿瘤潜力和确切的作用机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1